200M infrastructure deal, plasma merger & rare disease market surge

*Together with VantagePoint & Brownstone Research

Good day, 360!

Here are some of our top movers today. And don’t forget to join us in Market Masters - the hottest trading room around 🔥. Be the best prepared trader on the Street!

FOCUS LIST🔎

GRO - Up over 75% in pre after signing memorandum of understanding for ~$200m power line construction and $20m investment with Fictor Energia

XAGE - Up over 100% in pre after announcing merger with THPlasma and termination of 20/20 BioLabs transaction

SXTP - Up over 75% in pre after announcing potential human Babesiosis market size for ARAKODA® (tafenoquine): annual max TAM, sales of $245 million; cumulative through patent expiration, $1.1 billion

HOTLIST🔥

GRO - Up over 75% in pre after signing memorandum of understanding for ~$200m power line construction and $20m investment with Fictor Energia 

Brazil Potash Corp. (GRO) engages in the exploration and development of potash properties in Brazil. The company holds interest in the Autazes project located in the state of Amazonas, Brazil.

In the after-hours yesterday, the company announced the signing of a non-binding Memorandum of Understanding (MOU) with Fictor & WTT S.A., part of the infrastructure division of Fictor Group, a leading Brazilian private equity firm. 

The MOU outlines terms for Fictor Energia to fund ~$200 million in power transmission construction costs for the Autazes Project while securing long-term energy supply and a $20 million strategic equity investment.

Energia plans to invest $20 million equity into Brazil Potash in two tranches: 1) $2 million upon signing of the definitive partnership agreement; and 2) $18 million upon receipt of the power line installation license.

The power transmission infrastructure would be expected to be completed and operational by July 2029, aligning with the Autazes Project's planned production timeline.

Shares of GRO traded up over 75% in the pre-market in reaction to the news.

The $2.20 area acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $2.60, $2.85 and then the after-hours high at $2.97. Beyond that, $3.10 and $3.60 come into play.

Below $2.20, targets to the downside are $2.05, $1.70, $1.55 and then a gap fill at $1.45.  

XAGE - Up over 100% in pre after announcing merger with THPlasma and termination of 20/20 BioLabs transaction

Longevity Health Holdings, Inc. (XAGE) is a company focused on human longevity and healthy aging.

In  the after-hours yesterday, the company announced the execution of a definitive merger agreement with True Health Inc., a leading player in the fast growing plasma collection industry under the THPlasma brand (“THPlasma”), to combine the companies in an all-stock transaction. 

Following the closing of the Merger, the combined company is expected to continue to trade on Nasdaq under the symbol “XAGE.”

THPlasma operates a chain of plasma collection centers in the Northeast United States. The Company has long-term partnerships with key Industry players for guaranteed sales offtake up to $100 million per year.

Shares of XAGE traded up over 100% in the pre-market in reaction to the news.

The $4.50 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $5, $5.50 and then the pre-market high at $5.94. Beyond $5.94, targets to the upside are $6.80, $7.50 and then $9.31.

Below $4.50, targets to the downside are $4, $3.80, $3.50, $3.10 and then a gap fill at $2.65.

SXTP - Up over 75% in pre after announcing potential human Babesiosis market size for ARAKODA® (tafenoquine): annual max TAM, sales of $245 million; cumulative through patent expiration, $1.1 billion  

60 Degrees Pharmaceuticals, Inc. (SXTP) is a pharmaceutical company focused on developing new medicines for infectious diseases.

In the pre-market this morning, the company announced it has determined the maximum size of the commercial market for ARAKODA® (tafenoquine) for treatment of human babesiosis to be 380,000 patients/$245,000,000 in sales annually, with a cumulative TAM of 1.17 million patients/$1.1 billion through patent expiration in 2035.

Human babesiosis is a serious and debilitating emerging tick-borne illness often found as a co-infection in patients with Lyme Disease. There is a substantial unmet medical need due to the lack of FDA-approved treatments and the frequent generation of resistance associated with repeated use of generic drugs to manage persistent disease.

Three 60 Degrees Pharmaceuticals-sponsored clinical trials (NCT06478641, NCT06207370, NCT06656351) are underway or planned to evaluate tafenoquine’s safety and efficacy in treating humans diagnosed with babesiosis. Data are expected from one or more of these studies in the first half of 2026 and will be used as part of a planned New Drug Application (NDA) submission to the U.S. Food and Drug Administration for babesiosis, anticipated in 2026.

Shares of SXTP traded up over 75% in the pre-market in reaction to the news.

The $2.40 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $2.60, $2.80, $3, $4 and then the the pre-market high at $4.50.

Below $2.40, targets to the downside are $2.30, $2.20, a gap fill at $2.17 and then $2 below that.

 MARKET NEWS 📰

Don't miss out on our MOBILE ALERTS!  Some of these alerts have rocketed past the MOON 🌝.  Simply text “RAGE” to 1-(888) 487-1534 📲.

*Disclosure: By texting “RAGE” to 1-(888) 487-1534, you agree to receive promotional messages sent via an autodialer. You also agree to the terms of service and privacy policy. This agreement isn’t a condition of any purchase. Message frequency varies. Message and data rates may apply. Reply STOP to opt out; HELP for more information.